Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer.

Ying LiuNing ZhangHanwen ZhangLijuan WangYi DuanXiaolong WangTong ChenYiran LiangYaming LiXiaojin SongChen LiDianwen HanBing ChenWenjing ZhaoQifeng Yang

Published in: Drug design, development and therapy (2020)

Fatostatin could induce ER degradation by K48-linked polyubiquitination, which was the key mechanism contributing to tamoxifen inhibition of PI3K-AKT-mTOR signalling in breast cancer. Fatostatin may have a promising clinical use for ER-positive breast cancer patients.

Keyphrases

positive breast cancer
estrogen receptor
breast cancer cells
endoplasmic reticulum
cancer therapy
drug delivery